Skip to main content
OpenTrials
Completed

NCT Number: NCT02826343

New Technology to Assess Treatment for Chronic Obstructive Pulmonary Disease (COPD)

First, the investigators will image patients with hyperpolarized xenon (Xe) magnetic resonance imaging (MRI) to develop the technique of hyperpolarized xenon MRI at the University of Virginia (UVA). Magnetic Resonance (MR) sequences will need to be developed and optimized for the equipment at UVA. These sequences will need to be evaluated in healthy adults for comparison with results obtained and in adults with lung diseases to optimize the sequences for the detection and evaluation of lung diseases. The MR pulse sequences need to be optimized for the parameters of a human MR coil and the gas exchange characteristics in healthy and diseased lungs.

Second, the investigators propose to exploit the power of Xe129 MRI as a diagnostic tool to monitor therapeutic responses of a combination inhaler, Advair, which contains a long-acting beta-adrenoceptor agonist (LABA) and an inhaled corticosteroid (ICS) - two major classes of the current COPD therapeutics. The investigators will characterize the functional changes of the lungs with COPD at baseline, and investigate the responses of the lungs to the treatment after a three-month trial. Also the investigators will compare corresponding results obtained by Xe129 dissolved phase (DP) MRI to the results obtained by gadolinium-based dynamic contrast-enhanced perfusion MRI (perfusion MRI) and high resolution computed tomography (HRCT) of the lung to indirectly validate the Xe129 DP MRI technique. The investigators anticipate that the results from this project will greatly improve the investigators understanding of the lung functional responses of COPD subjects to current therapeutics. Also, the investigators expect that this project will provide evidence to consider Xe129 MRI as a diagnostic strategy to assess and monitor therapeutic responses of existing and new pharmaceuticals, and thus Xe129 MRI will stimulate development of novel therapies for COPD in the future

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Pulmonary Disease, Chronic Obstructive Chronic Disease Disease Attributes Lung Diseases Lung Diseases, Obstructive Pathologic Processes Pathological Conditions, Signs and Symptoms Respiratory Tract Diseases

Age range

18 year–85 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Early Phase 1

Primary location

University of Virginia

Charlottesville, Virginia, 22908, United States

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Subjects should be at their clinical baseline on the day of imaging
  • Subjects must be clinically stable in order to participate in the study
  • Smoking history >10 pack years
  • Subjects must not be currently taking Advair or have taken it within 4 weeks prior to screening
  • No subject will be withdrawn from Advair to participate in this study

The subjects with COPD will be categorized according to the Global Initiative for Chronic Obstructive Lung Disease (GOLD) COPD severity classification:

  • Class 1: forced expiratory volume at one second (FEV1)/forced vital capacity (FVC) < 70 and FEV1 > 80% predicted;
  • Class 2: FEV1/FVC < 70 and 50% < FEV1 < 80% predicted;
  • Class 3: FEV1/FVC < 70 and 30% < FEV1 < 50% predicted;
  • Class 4: FEV1/FVC < 70 and FEV1 < 30% predicted

Exclusion criteria

  • Continuous oxygen use at home
  • Blood oxygen saturation of 92% less than as measured by pulse oximetry on the day of imaging
  • FEV1 percent predicted less than 25%
  • Pregnancy or lactation
  • Claustrophobia, inner ear implants, aneurysm or other surgical clips, metal foreign bodies in eye, pacemaker or other contraindication to MR scanning
  • Subjects with any implanted device that cannot be verified as MRI compliant will be excluded.
  • Chest circumference greater than that of the xenon MR and/or helium coil. The circumference of the coil is approximately 42 inches.
  • History of congenital cardiac disease, chronic renal failure, or cirrhosis.
  • Inability to understand simple instructions or to hold still for approximately 10 seconds.
  • History of respiratory infection within 2 weeks prior to the MR scan
  • History of myocardial infarction (MI) , stroke and/or poorly controlled hypertension.
  • Known hypersensitivity to albuterol or any of its components, or levalbuterol
  • Glomerular filtration rate (GFR) < 60 ml/min/1.73 m2 or known hypersensitivity to Gd-contrast agents based on a serum creatinine drawn within 30 days of the MRI
  • Acute kidney injury
  • History of paraproteinemia syndromes such as multiple myeloma
  • Hepatorenal syndrome
  • Liver transplant

Treatment and study plan

Xenon129 MRI imaging

Drug

subjects will receive at baseline and 3 month post Advair intervention (See next intervention)

Gadolinium MRI

Drug

subjects will receive at baseline and 3 month post Advair intervention (See next intervention)

Advair (250mcg/50mcg) one puff twice a day

Drug

subjects will receive for 3 month duration between baseline and 3 month post Xenon129 MRI imaging and Gadolinium MRI.

Primary outcomes

  1. Improvement in pulmonary airflow physiology detected by Xenon129 MRI

    Time frame: From baseline to 3 month post treatment with Advair

    MRI will determine anticipated improvement in patients' airflow limitation correlation ventilation defect.

  2. Improvement in pulmonary gas exchange physiology detected by Xenon129 MRI

    Time frame: From baseline to 3 month post treatment with Advair

    Dissolved phase Xe129 of the MRI will determine anticipated improvement in patients' gas exchange capacity in lung tissues correlating with tissue damage caused by COPD.

Secondary outcomes

  1. Improvement in clinical pulmonary function test

    Time frame: From baseline to 3 month post treatment with Advair

    Pulmonary function test will measure anticipated improvement in patients lung function after using Advair.

  2. St. George's Respiratory Questionnaire

    Time frame: From baseline to 3 month post treatment with Advair

    St. George's Respiratory Questionnaire will measure anticipated improvement in subjective symptoms of patients.

  3. Baseline Dyspnea Index

    Time frame: From baseline to 3 month post treatment with Advair

    Baseline Dyspnea Index will measure anticipated improvement in subjective symptoms of patients.

  4. Transition Dyspnea Index

    Time frame: From baseline to 3 month post treatment with Advair

    Transition Dyspnea Index will measure anticipated improvement in subjective symptoms of patients.

  5. Chronic Respiratory Questionnaire

    Time frame: From baseline to 3 month post treatment with Advair

    Chronic Respiratory Questionnaire will measure anticipated improvement in subjective symptoms of patients.

  6. BODE score

    Time frame: From baseline to 3 month post treatment with Advair

    BODE score will measure anticipated improvement in subjective symptoms of patients.

  7. GOLD Stage

    Time frame: From baseline to 3 month post treatment with Advair

    GOLD Stage will measure anticipated improvement in subjective symptoms of patients.

Sponsors and collaborators

Lead sponsor

University of Virginia

Other

Collaborators

  • National Institutes of Health (NIH)

Registry information

Official study title

Xe129 Magnetic Resonance Imaging of the Lung: A New Technology to Assess Treatment for COPD

Important dates

Study start
2016
Primary completion
2018
Study completion
2018
First posted
Jul 11, 2016
Registry last updated
Nov 4, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.